Earnings
Kiniksa Sets Second-Half 2027 Data Date For Monthly Heart Drug, Eyes 2028-2029 Launch
Arcalyst is on track for over $1 billion in 2026 sales and is paying for the pipeline, management said.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
Arcalyst is on track for over $1 billion in 2026 sales and is paying for the pipeline, management said.
Earnings
The CEO said at least 25% reported growth is in reach next year, with formal guidance due toward the end of February.
Earnings
Capital equipment orders rose mid-teens, but buyers are slow to commit, so most of the revenue lands in 2027, the CEO said.
Earnings
Dorman's CEO said demand for recreational off-road accessories has softened, while utility-vehicle parts held up.
Earnings
Dorman narrowed its 2026 outlook to sales growth of 2% to 3% and adjusted EPS of $8.50 to $8.70, with softer DIY demand and price cuts as drivers.
SEC Filings
The notes would be issued by Blackstone Reg Finance Co. and backed by the parent and five Holdings partnerships.
Deals
Adjusted EBITDA rose 47% while go-private costs and a contingent-consideration charge deepened the loss ahead of a $32.50-a-share buyout.
Earnings
The welding maker's organic sales rose 14.5%, led by volume, and adjusted earnings per share reached $2.98 from $2.47.
SEC Filings
David Chaikof, a former Torys partner, joins as an independent director after serving as the company's external counsel for more than a decade.
Earnings
A $99.7 million tariff-refund haul drove most of the nine-month cash flow jump, while third-quarter margin fell to 39.4%.
SEC Filings
The San Diego company's lead RNA drug, ATR 1072, enters a trial of about 37 participants, with first proof-of-concept data expected in the second half of 2027.
Earnings
The homesite option platform raised its fourth-quarter cash-earnings outlook and put $1.1 billion behind Dream Finders' Beazer deal.